International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Epratuzumab (Primary) ; Asparaginase; Asparaginase; Crisantaspase; Crisantaspase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Mitoxantrone; Prednisolone; Tioguanine; Vincristine; Vindesine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms IntReALL SR 2010
- 21 Feb 2024 This trial has been completed in Czech Republic. (Global end date: 31 July 2023).
- 31 Jan 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 16 Jan 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.